Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
加拉帕戈斯和Adaptimmune進入臨床合作，使用分散式製造平台許可下一代TCR T細胞療法治療癌症
- Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer
- Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform
- Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development
- Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales
- Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications
- Adaptimmune和galapagos將進行臨床概念驗證試驗，評估在Galapagos的分散式製造平台上生產的uza-cel（下一代MAGE-A4 TCR T細胞療法）在頭頸癌患者中的安全性和有效性。
- 到目前爲止，在使用Adaptimmune的集中製造平台的1期試驗中，uza-cel在頭頸癌中顯示出鼓舞人心的結果，5名患者中的4名出現了部分緩解。
- 初始體外測試表明，Galapagos的分散式製造平台生產的uza-cel顯示出有利數據，支持進一步的臨床開發。Adaptimmune將獲得1億美元的初始支付，包括7千萬美元的前期支付和3千萬美元的研發資金，最高可達1億美元的期權行權費，最高可達4.65億美元的額外開發和銷售里程碑付款，以及按淨銷售額分層計算的版稅。
- Galapagos已獲授權獨家許可，在頭頸癌和潛在的未來實體腫瘤癌症適應症中全球開發和商業化uza-cel。
資訊熱榜
更新時間